The Mindbloom Method is clinically validated across the 3 largest peer-reviewed studies of ketamine therapy ever published.
All three showed stellar outcomes across anxiety, depression, PTSD, and more.
Mindbloom’s research archive
At-home, telehealth-supported ketamine therapy for veterans with depression, anxiety, and PTSD: Findings from a real-world, observational study
Mindbloom is committed to advancing psychedelic science, with the largest body of research of any ketamine therapy provider following more than 11,000 clients.
Symptom improvement
reported symptom improvement in anxiety & depression1
reported meaningful PTSD symptom improvement2
with suicidal thoughts reported them fully resolved within program completion1
Speed to results
Not only does our at-home ketamine program greatly reduce feelings of anxiety and depression, it does so in hours or days—not months.
Mindbloom1
Hours to days
Tradtional SSRIs3
4-8 weeks
With traditional treatments, people might not notice improvements for up to 2 months—that is, if they see improvements at all. Because of ketamine’s fast-acting nature, most Mindbloom clients report symptom relief after just 4 sessions, and some after their very first session.
Side effects
experienced no side effects with Mindbloom treatment1
Many come to Mindbloom frustrated by side effects of their SSRIs (weight gain, emotional flatness, loss of libido). Our peer-reviewed studies demonstrate the high tolerability profile of this treatment. The mild effects that may occur typically clear within hours. That's why people finish their programs, and why Mindbloom’s care model actually works.
Treatment comparisons
When compared to studies of alternative treatments, Mindbloom’s symptom improvements were stronger and achieved in just 4 weeks vs 2+ months.
Sleep
The largest ketamine sleep analysis to date saw clients report significant improvement—better than Ambien, trazodone, melatonin, and CBT for insomnia—often visible after just 2 Mindbloom sessions.7
saw clinically meaningful improvement in sleep
Veterans
The largest evaluation of ketamine therapy in veterans ever published saw tremendous outcomes across anxiety, depression, and PTSD.8
Ketamine has been used safely and effectively for mental health for 20+ years.
With over 300 major studies conducted across 50+ institutions, clinical research continues to demonstrate that ketamine can be successfully used to treat mental health conditions and their symptoms.
Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism
Narrative review summarizing recent data and ongoing clinical trials on psychedelic medicines, highlighting their potential in treating a wide range of conditions.
Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial
Prior trials suggest that intravenous racemic ketamine is a highly effective for treatment-resistant depression (TRD), but phase 3 trials of racemic ketamine are needed.
Ketamine and psychotherapy for the treatment of psychiatric disorders: systematic review
Systematic review of studies combining psychotherapy with ketamine for psychiatric disorders.
Real-world depression, anxiety and safety outcomes of intramuscular ketamine treatment: A retrospective descriptive cohort study
IM ketamine is being utilized to treat psychiatric outpatients with multiple mental illnesses not limited to depression. Average depression and anxiety levels significantly improve throughout IM ketamine treatment and do not regress to baseline during patients’ maintenance treatment phase. Prospective studies are recommended to confirm the long-term effectiveness and safety of IM ketamine.
You deserve proof, not promises.
Hull TD, et al. Journal of Affective Disorders (2022). https://doi.org/10.1016/j.jad.2022.07.004.
Parks AC, et al. Journal of Medical Internet Research (2026). https://doi.org/10.2196/92647.
Trivedi M,. et al. American Journal of Psychiatry (2006). https://doi.org/10.1176/appi.ajp.163.1.28.
Cuijpers P, et al. Acta Psychiatrica Scandinavica (2021). https://doi.org/10.1111/acps.13335.
McInnes L. A., et al. Journal of Affective Disorders (2022). https://doi.org/10.1016/j.jad.2021.12.097.
Mathai DS, et al. Journal of Affective Disorders (2024). https://doi.org/10.1016/j.jad.2024.05.131
Swain et al., Research Square (2026). https://doi.org/10.21203/rs.3.rs-9553669/v1.
Lutz et al., Manuscript in preparation (2026)
